Amylyx Pharmaceuticals
AMLX
206 hedge funds and large institutions have $2.07B invested in Amylyx Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 71 increasing their positions, 59 reducing their positions, and 13 closing their positions.
292% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 13
291% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $2.96M
30% more capital invested
Capital invested by funds: $1.59B → $2.07B (+$479M)
20% more funds holding
Funds holding: 171 → 206 (+35)
20% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 59
0.12% more ownership
Funds ownership: 103.27% → 103.39% (+0.12%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$26.4M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$16.3M |
| 3 |
Morgan Stanley
New York
|
+$14.8M |
| 4 |
Aberdeen Group
Edinburgh,
United Kingdom
|
+$11.4M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$10.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$25.7M |
| 2 |
AC
Almitas Capital
Santa Monica,
California
|
-$17.7M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$16.2M |
| 4 |
Barclays
London,
United Kingdom
|
-$14.2M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11M |
AMLX Hedge Fund Activity: Q2 2026 in Review
206 of the 8,299 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q2 2026, worth a combined $2.07B — up 30% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new AMLX positions and 13 closed out — a net gain of 38 holders — while 71 added to existing stakes and 59 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $26.4M. The largest seller was Adage Capital Partners, cutting an estimated $25.7M.
- 206 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q2 2026, up from 171 in Q1 2026.
- Funds reported $2.07B of Amylyx Pharmaceuticals stock for Q2 2026, up 30% quarter-over-quarter.
- 51 funds opened new Amylyx Pharmaceuticals positions in Q2 2026 and 13 closed out, a net change of +38 holders.
- The largest Amylyx Pharmaceuticals buyer in Q2 2026 was JP Morgan Chase, an estimated $26.4M added.
- The largest Amylyx Pharmaceuticals seller in Q2 2026 was Adage Capital Partners, an estimated $25.7M sold.
Based on aggregated 13F filings for Q2 2026.